VIOBAC

Prevents catheter associated infections

Catheter-associated urinary tract infections (CAUTI) have been reported as the most common hospital acquired infection in the world being responsible for up to 40% of all hospital infections, with more than 1 million cases per year in the US alone. Approximately 25% of hospitalized patients will undergo urinary catheterization, and nearly 30% of these will develop CAUTI.

VIOBAC has invented a solution - BaLu™ - to the problem

BaLu™ is an innovative UV light solution designed to reduce catheter-associated infections. The solution is a click-on device developed to prevent bacteria from getting into the patients urinary tract system - and will thereby prevent unnecessary urinary tract infections from happening when using a catheter.

VIOBAC has been voted the best university startup in the world within the health category (goal 3) with incorporation of the UN’s 17 Sustainable Development Goals, 2019.

VIOBAC has been chosen as one of the 10 selected participants for Nordic Health Tech Talents (NHTT) 2019 hosted by Venture Cup. VIOBAC was named as one of the winners of the 2019 EIT Health Scandinavia Headstart Award.

VIOBAC and Prevas
An assignment where technology meets societal benefit, and where innovation truly makes a difference.

Henrik Møller, President Prevas A/S

From idea to innovation

Prevas has supported VIOBAC throughout the entire development journey – from hardware development and software solutions to mechanical design, project management and quality assurance. An assignment where technology meets societal benefit, and where innovation truly makes a difference.

Our expertice

SDG